Resultats globals: 3 registres trobats en 0.02 segons.
Articles, 3 registres trobats
Articles 3 registres trobats  
1.
9 p, 1.3 MB Association of baseline absolute neutrophil counts and survival in patients with metastatic colorectal cancer treated with second-line antiangiogenic therapies : exploratory analyses of the RAISE trial and validation in an electronic medical record data set / Grothey, Axel (Mayo Clinic) ; Yoshino, Takayuki (National Cancer Center Hospital East) ; Bodoky, Gyorgy (St László Hospital) ; Ciuleanu, Tudor (The Oncology Institute Prof Dr Ion Chiricută and Iuliu Hațieganu University of Medicine and Pharmacy) ; Garcia-Carbonero, Rocio (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ; García-Alfonso, Pilar (Hospital General Universitario Gregorio Marañón) ; Van Cutsem, Eric (University Hospitals Leuven - KU Leuven) ; Muro, Kei (Aichi Cancer Center Hospital) ; Mytelka, Daniel S (Formerly of Eli Lilly and Company) ; Li, Li (Eli Lilly and Company) ; Lipkovich, Olga (Eli Lilly and Company) ; Hsu, Yanzhi (Eli Lilly and Company) ; Sashegyi, Andreas (Eli Lilly and Company) ; Ferry, David (Eli Lilly and Company) ; Nasroulah, Federico (Eli Lilly Argentina) ; Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ; Universitat Autònoma de Barcelona
In the RAISE trial, ramucirumab+leucovorin/fluorouracil/irinotecan (FOLFIRI) improved the median overall survival (mOS) of patients with previously treated metastatic colorectal cancer versus patients treated with placebo+FOLFIRI but had a higher incidence of neutropaenia, leading to more chemotherapy dose modifications and discontinuations. [...]
2018 - 10.1136/esmoopen-2018-000347
ESMO Open, Vol. 3 (april 2018)  
2.
8 p, 1.4 MB Comprehensive Characterization of the Mutational Landscape in Localized Anal Squamous Cell Carcinoma / Trilla-Fuertes, Lucía (Biomedica Molecular Medicine SL, C/Faraday 7, 28049, Madrid, Spain) ; Ghanem, Ismael (Medical Oncology Department, Hospital Universitario La Paz, Paseo de la Castellana 261, 28046, Madrid, Spain) ; Maurel, Joan (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; G-Pastrián, Laura (Molecular Pathology and Therapeutic Targets Group, Hospital Universitario La Paz-IdiPAZ, Paseo de la Castellana 261, 28046, Madrid, Spain) ; Mendiola, Marta (Centro de Investigación Biomédica en Red de Cáncer) ; Peña, Cristina (Pathology Department, Hospital Universitario La Paz, Paseo de la Castellana 261, 28046, Madrid, Spain) ; López-Vacas, Rocío (Molecular Oncology & Pathology Lab, Institute of Medical and Molecular Genetics-INGEMM, Hospital Universitario La Paz-IdiPAZ, Paseo de la Castellana 261, 28046, Madrid, Spain) ; Prado-Vázquez, Guillermo (Biomedica Molecular Medicine SL, C/Faraday 7, 28049, Madrid, Spain) ; López-Camacho, Elena (Molecular Oncology & Pathology Lab, Institute of Medical and Molecular Genetics-INGEMM, Hospital Universitario La Paz-IdiPAZ, Paseo de la Castellana 261, 28046, Madrid, Spain) ; Zapater-Moros, Andrea (Molecular Oncology & Pathology Lab, Institute of Medical and Molecular Genetics-INGEMM, Hospital Universitario La Paz-IdiPAZ, Paseo de la Castellana 261, 28046, Madrid, Spain) ; Heredia Soto, Victoria (Hospital Universitario La Paz (Madrid)) ; Cuatrecasas, Miriam (Hospital Clinic, CIBERehd. Department of Pathology) ; García-Alfonso, Pilar (Hospital General Universitario Gregorio Marañón) ; Capdevila, Jaume (Vall d'Hebron Institut d'Oncologia) ; Conill, Carles (Hospital Clinic, CIBERehd. Department of Pathology) ; García-Carbonero, Rocío (Hospital Universitario 12 de Octubre (Madrid)) ; Heath, Karen E. (Instituto de Investigación Hospital Universitario La Paz) ; Ramos-Ruiz, Ricardo (Genomics Unit Cantoblanco, Parque Científico de Madrid, C/ Faraday 7, 28049, Madrid, Spain) ; Llorens, Carlos (Biotechvana SL, Parque Científico de Madrid, C/ Faraday 7, 28049, Madrid, Spain) ; Campos-Barros, Ángel (Instituto de Investigación Hospital Universitario La Paz) ; Gámez-Pozo, Angelo (Molecular Oncology & Pathology Lab, Institute of Medical and Molecular Genetics-INGEMM, Hospital Universitario La Paz-IdiPAZ, Paseo de la Castellana 261, 28046, Madrid, Spain) ; Feliu, Jaime (Universidad Autónoma de Madrid) ; Vara, Juan Ángel Fresno (Molecular Oncology & Pathology Lab, Institute of Medical and Molecular Genetics-INGEMM, Hospital Universitario La Paz-IdiPAZ, Paseo de la Castellana 261, 28046, Madrid, Spain)
Anal squamous cell carcinoma (ASCC) is a rare neoplasm. Chemoradiotherapy is the standard of care, with no therapeutic advances achieved over the past three decades. Thus, a deeper molecular characterization of this disease is still necessary. [...]
2020 - 10.1016/j.tranon.2020.100778
Translational Oncology, Vol. 13 (may 2020)  
3.
11 p, 912.9 KB Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice : a retrospective cross-sectional analysis / Capdevila, Jaume (Hospital Universitari Vall d'Hebron) ; Sevilla, Isabel (Hospital Universitario Virgen de la Victoria) ; Alonso, Vicente (Medical Oncology Department, Hospital Universitario Miguel Servet) ; Antón Aparicio, Luís (Complejo Hospitalario Universitario A Coruña) ; Jiménez Fonseca, Paula (Hospital Universitario Central de Asturias) ; Grande, Enrique (Hospital Universitario Ramón y Cajal) ; Reina, Juan José (Hospital Universitario Virgen de la Macarena) ; Manzano, José Luís (Hospital Universitari Vall d'Hebron) ; Alonso Lájara, Juan Domingo (Hospital Universitario Virgen de la Arrixaca (Múrcia)) ; Barriuso, Jorge (Hospital Universitario La Paz (Madrid)) ; Castellano, Daniel (Hospital Universitario 12 de Octubre (Madrid)) ; Medina, Javier (Complejo Hospitalario de Toledo) ; López, Carlos (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ; Segura, Ángel (Hospital Universitario La Fe University Hospital) ; Carrera, Sergio (Hospital Universitario de Cruces) ; Crespo, Guillermo (Hospital Universitario de Burgos) ; Fuster, José (Hospital Universitario Son Dureta) ; Munarriz, Javier (Hospital Provincial de Castelló) ; García Alfonso, Pilar (Hospital Gregorio Marañón (Madrid)) ; Universitat Autònoma de Barcelona
Based on the mechanism of action, combining somatostatin analogues (SSAs) with mTOR inhibitors or antiangiogenic agents may provide synergistic effects for the treatment of patients with neuroendocrine tumours (NETs). [...]
2015 - 10.1186/s12885-015-1512-6
BMC Cancer, Vol. 15 (july 2015)  

Vegeu també: autors amb noms similars
1 García-Alfonso, P
4 García-Alfonso, P.
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.